Therapeutic Properties of Honey for the Management of Wounds; Is There a Role in the Armamentarium of Diabetic Foot Ulcer Treatment? Results From In vitro and In vivo Studies

2021 ◽  
pp. 153473462110268
Author(s):  
Ioanna A. Anastasiou ◽  
Ioanna Eleftheriadou ◽  
Anastasios Tentolouris ◽  
Georgia Samakidou ◽  
Nikolaos Papanas ◽  
...  
Keyword(s):  
Wound Healing ◽  
Diabetic Foot ◽  
Diabetic Animal ◽  
Cochrane Library ◽  
Foot Ulcers ◽  
Diabetic Foot Ulcers ◽  
Diabetic Wound ◽  
Diabetic Wound Healing ◽  
Therapeutic Properties

Diabetic foot ulcers are one of the most dreadful complications of diabetes mellitus and efforts to accelerate diabetic wound healing are of paramount importance to prevent ulcer infections and subsequent lower-limb amputations. There are several treatment approaches for the management of diabetic foot ulcers and honey seems to be a safe and cost-effective therapeutic approach on top of standard of care. The aim of this review was to summarize the therapeutic properties of honey and the data regarding its possible favorable effects on diabetic wound healing. A literature search of articles from 1986 until April 2021 was performed using MEDLINE, EMBASE, and the Cochrane Library to assess for studies examining the therapeutic wound healing properties of honey, it's in vitro effect, and the efficacy and/or mechanism of action of several types of honey used for the treatment of diabetic animal wounds. Honey has antioxidant, anti-inflammatory, and antibacterial properties and in vitro studies of keratinocytes and fibroblasts, as well as studies in diabetic animal models show that treatment with honey is associated with increased re-epithelialization and collagen production, higher wound contraction, and faster wound healing. The use of honey could be a promising approach for the management of diabetic foot ulcers.

Single Cell RNA-Seq Analyses of Healthy Lower Extremity Skin and Diabetic Foot Ulcers Uncover Distinct Immune Landscape of Diabetic Wound Healing

Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 647-P ◽  
Author(s):  
GEORGIOS THEOCHARIDIS ◽  
SWATI S. BHASIN ◽  
KONSTANTINOS KOUNAS ◽  
MANOJ K. BHASIN ◽  
ARISTIDIS VEVES
Keyword(s):  
Wound Healing ◽  
Lower Extremity ◽  
Single Cell ◽  
Diabetic Foot ◽  
Foot Ulcers ◽  
Diabetic Foot Ulcers ◽  
Diabetic Wound ◽  
Rna Seq ◽  
Diabetic Wound Healing

scholarly journals PENGARUH SENAM KAKI TERHADAP PENYEMBUHAN LUKA DIABETIK PADA PASIEN DIABETES MELLITUS DI RUANG RAWAT INAP RA1 DAN RA2 PENYAKIT DALAM RSUP. H. ADAM MALIK MEDAN

2020 ◽  
Vol 3 (1) ◽  
pp. 265-271
Author(s):  
Dewi Astuti Pasaribu ◽  
Septian Mixrova Sebayang
Keyword(s):  
Diabetes Mellitus ◽  
Wound Healing ◽  
Diabetic Foot ◽  
Intervention Group ◽  
T Test ◽  
Foot Ulcers ◽  
Diabetic Foot Ulcers ◽  
Diabetic Wound ◽  
Post Test ◽  
Diabetic Wound Healing

Diabetic foot ulcers (DFUs) are a serious complication of diabetes mellitus (DM) that can be slow to heal, result in repeated hospitalizations, require intense and costly treatment, and reduce the quality of life. The purpose of this study was to investigate the effect of foot exercises on wound healing in type 2 diabetic patients with a diabetic foot ulcer. Quasi-experimental study using before and after changes to wound healing in between February until May 2019.Thirty patients from an inpatient rooms with ulcers who met study criteria agreed to participate. Subjects were recruited by the researchers in the hospital where they received treatment. Data were collected using investigator-developed forms: patient information form and the diabetic foot exercises log. Patients in the intervention group received standard wound care and performed daily foot exercises for 3 week. Diabetic wound healing of the patients in the intervention were examined and measured at the 3rd weeks. To analyze and compare the data, frequency distribution, mean (standard deviation), and the paired samples t test were used. The mean of diabetic wound healing were 3.50, 2.90, and 2.40 in the study intervention group in 1st, 2nd, and 3rd weeks, respectively. Significant differences were found between diabetic wound healing in pre-test and post-test group (p=0.041). An important finding in this study was the DFU area decreased more in those who exercised more. Findings suggest foot exercises should be included in the treatment plan when managing patients with diabetic foot ulcers.     Abstrak Luka kaki diabetic adalah suatu komplikasi yang serius pada diabetes mellitus dimana dapat memperlambat penyembuhan, hospitalisasi berulang, membutuhkan pengobatan yang mahal dan menurunkan kualitas hidup. Tujuan penelitian ini adalah untuk mengetahui efek senam kaki terhadap penyembuhan luka pada pasien diabetes mellitus tipe 2. Jenis penelitian Quasi eksperimen digunakan untuk melihat perubahan sebelum dan sesudah penyembuhan luka dari Februari sampai Mei 2019. Tiga puluh pasien dari ruang inap dengan luka menjadi kriteria inklusi sebagai responden. Responden direkrut oleh peneliti di rumah sakit dimana pasien sedang menjalani perawatan. Pengumpulan data menggunakan kuesioner data demografi dan lembar observasi penyembuhan luka. Pasien akan diberikan latihan selama 3 minggu. Penyembuhan luka diabetic pada pasien akan dikaji dan diukur sampai minggu ke tiga. Untuk menganalisis dan membandingkan data, distribusi frekuensi, mean (standar deviasi), dan paired t test dilakukan. Mean penyembuhan luka diabetik diantaranya 3.50, 2.90 dan 2.40 pada kelompok intervensi pada minggu pertama, kedua, dan ketiga secara berurutan. Perbedaan signifikan penyembuhan luka diabetic antara kelompok pre-test dan post-test (p=0.041). Suatu temuan penting bahwa area luka kaki diabetic semakin menurun pada orang yang melakukan senam. Temuan ini juga senam kaki sebaiknya dimasukkan dalam rencana perawatan ketika merawat pasien dengan luka kaki diabetik.

scholarly journals Novel long non-coding RNA lnc-URIDS delays diabetic wound healing by targeting Plod1

2020 ◽  
Author(s):  
Ada Admin ◽  
Mengdie Hu ◽  
Yuxi Wu ◽  
Chuan Yang ◽  
Xiaoyi Wang ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Wound Healing ◽  
Diabetic Foot ◽  
Dermal Fibroblasts ◽  
Diabetic Wound ◽  
Delayed Wound Healing ◽  
Impaired Wound Healing ◽  
Diabetic Wound Healing

Impaired wound healing is one of the main reasons that leads to diabetic foot ulcerations. However, the exact mechanism of delayed wound healing in diabetes mellitus is not fully understood. Long non-coding RNAs (lncRNAs) are widely involved in a variety of biological processes and diseases, including diabetes and its associated complications. Here, w<a>e identified a novel lncRNA MRAK052872, named lnc-URIDS (lncRNA <u>U</u>p<u>R</u>egulated <u>i</u>n <u>D</u>iabetic <u>S</u>kin), which regulates wound healing in diabetes mellitus. </a>Lnc-URIDS was highly expressed in diabetic skin and dermal fibroblasts treated with advanced glycation end products (AGEs). Lnc-URIDS knockdown promoted migration of dermal fibroblasts under AGEs treatment <i>in vitro</i> and accelerated diabetic wound healing <i>in vivo</i>. Mechanistically, <a>lnc-URIDS interacts with procollagen-lysine, 2-oxoglutarate 5-dioxygenase 1 (Plod1), a critical enzyme responsible for collagen cross-linking. </a><a>The binding of lnc-URIDS to Plod1 results in a decreased protein stability of Plod1, which ultimately leads to the dysregulation of collagen production and deposition and delays wound healing. Collectively, this study identifies a novel lncRNA that regulates diabetic wound healing by targeting Plod1. </a><a>The findings of the present study offer some insight into the potential mechanism for the delayed wound healing in diabetes and provide a potential therapeutic target for diabetic foot.</a>

scholarly journals Use of Cellular and Tissue-based Product in the Treatment of Diabetic Foot Ulcers

2016 ◽  
Vol 3 (2) ◽  
pp. 92-96
Author(s):  
Thomas E Serena ◽  
Raphael A Yaakov ◽  
Eliot N Mostow
Keyword(s):  
Wound Healing ◽  
Diabetic Foot ◽  
Chronic Wounds ◽  
Relevant Literature ◽  
Cost Of Care ◽  
Asia Pacific ◽  
Cochrane Library ◽  
Foot Ulcers ◽  
Economic Evaluations ◽  
Diabetic Foot Ulcers

ABSTRACT Introduction The prevalence of diabetes has been rising sharply and the rise in chronic wounds parallels this trend. Lower extremity ulcers present a serious complication for people with diabetes. While debridement of necrotic tissue and off-loading plays an important role in wound healing, many patients with diabetic foot ulcers (DFUs) fail to heal with standard of care (SOC) alone. Unresolved ulcers can lead to complications, such as osteomyelitis and amputation. There continues to be a need for the evaluation of novel wound therapies that can accelerate wound healing and lower the cost of care associated with DFUs. This paper presents recent evidence for the use of cellular and/or tissue-based products (CTPs) and offers an approach for selecting an appropriate CTP. Materials and methods A systematic literature search was conducted using PubMed, Embase, Medline, Cochrane library, and NHS Economic Evaluation Database. Full-length articles in English were assessed for relevance to select studies on effectiveness and economic evaluations. Additionally, Google Scholar was used to gather relevant literature on commonly used CTPs, including Apligraf®, EpiFix®, and Dermagraft®. Findings Results from randomized controlled trials (RCTs) provided evidence for the superior efficacy of CTPs over SOC alone in treatment of chronic DFUs. In recent studies evaluating commonly used CTPs, significantly higher number of DFUs achieved complete closure with EpiFix® when compared to either Apligraf® or Dermagraft®. While cost-effectiveness studies continue to be limited, current literature suggests that CTPs can decrease the long-term costs associated with the care of DFUs by increasing the healing rate, reducing recovery time, and lowering the risk of infection and complications. Cellular and/or tissue-based products (CTPs) may result in higher average number of ulcer-free months and lower average number of amputations or resections compared to SOC alone. How to cite this article Serena TE, Yaakov RA, Mostow EN. Use of Cellular and Tissue-based Product in the Treatment of Diabetic Foot Ulcers. J Foot Ankle Surg (Asia-Pacific) 2016;3(2):92-96.

scholarly journals Targeting MMP-9 in Diabetic Foot Ulcers

2019 ◽  
Vol 12 (2) ◽  
pp. 79 ◽  
Author(s):  
Jeffrey I. Jones ◽  
Trung T. Nguyen ◽  
Zhihong Peng ◽  
Mayland Chang
Keyword(s):  
Wound Healing ◽  
Diabetic Foot ◽  
Healing Process ◽  
Foot Ulcers ◽  
Wound Healing Process ◽  
Diabetic Foot Ulcers ◽  
Novel Approach ◽  
Medical Need ◽  
Diabetic Wound Healing ◽  
Diabetic Wounds

Diabetic foot ulcers (DFUs) are significant complications of diabetes and an unmet medical need. Matrix metalloproteinases (MMPs) play important roles in the pathology of wounds and in the wound healing process. However, because of the challenge in distinguishing active MMPs from the two catalytically inactive forms of MMPs and the clinical failure of broad-spectrum MMP inhibitors in cancer, MMPs have not been a target for treatment of DFUs until recently. This review covers the discovery of active MMP-9 as the biochemical culprit in the recalcitrance of diabetic wounds to healing and targeting this proteinase as a novel approach for the treatment of DFUs. Active MMP-8 and MMP-9 were observed in mouse and human diabetic wounds using a batimastat affinity resin and proteomics. MMP-9 was shown to play a detrimental role in diabetic wound healing, whereas MMP-8 was beneficial. A new class of selective MMP-9 inhibitors shows clinical promise for the treatment of DFUs.

scholarly journals Novel long non-coding RNA lnc-URIDS delays diabetic wound healing by targeting Plod1

2020 ◽  
Author(s):  
Ada Admin ◽  
Mengdie Hu ◽  
Yuxi Wu ◽  
Chuan Yang ◽  
Xiaoyi Wang ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Wound Healing ◽  
Diabetic Foot ◽  
Dermal Fibroblasts ◽  
Diabetic Wound ◽  
Delayed Wound Healing ◽  
Impaired Wound Healing ◽  
Diabetic Wound Healing

Impaired wound healing is one of the main reasons that leads to diabetic foot ulcerations. However, the exact mechanism of delayed wound healing in diabetes mellitus is not fully understood. Long non-coding RNAs (lncRNAs) are widely involved in a variety of biological processes and diseases, including diabetes and its associated complications. Here, w<a>e identified a novel lncRNA MRAK052872, named lnc-URIDS (lncRNA <u>U</u>p<u>R</u>egulated <u>i</u>n <u>D</u>iabetic <u>S</u>kin), which regulates wound healing in diabetes mellitus. </a>Lnc-URIDS was highly expressed in diabetic skin and dermal fibroblasts treated with advanced glycation end products (AGEs). Lnc-URIDS knockdown promoted migration of dermal fibroblasts under AGEs treatment <i>in vitro</i> and accelerated diabetic wound healing <i>in vivo</i>. Mechanistically, <a>lnc-URIDS interacts with procollagen-lysine, 2-oxoglutarate 5-dioxygenase 1 (Plod1), a critical enzyme responsible for collagen cross-linking. </a><a>The binding of lnc-URIDS to Plod1 results in a decreased protein stability of Plod1, which ultimately leads to the dysregulation of collagen production and deposition and delays wound healing. Collectively, this study identifies a novel lncRNA that regulates diabetic wound healing by targeting Plod1. </a><a>The findings of the present study offer some insight into the potential mechanism for the delayed wound healing in diabetes and provide a potential therapeutic target for diabetic foot.</a>

scholarly journals 1,25-Dihydroxyvitamin D3 Induces LL-37 and HBD-2 Production in Keratinocytes from Diabetic Foot Ulcers Promoting Wound Healing: An In Vitro Model

PLoS ONE ◽  
2014 ◽  
Vol 9 (10) ◽  
pp. e111355 ◽  
Author(s):  
Irma Gonzalez-Curiel ◽  
Valentin Trujillo ◽  
Alejandra Montoya-Rosales ◽  
Kublai Rincon ◽  
Bruno Rivas-Calderon ◽  
...  
Keyword(s):  
Wound Healing ◽  
Diabetic Foot ◽  
In Vitro Model ◽  
Foot Ulcers ◽  
Diabetic Foot Ulcers ◽  
Dihydroxyvitamin D3 ◽  
1,25 Dihydroxyvitamin D3 ◽  
Vitro Model

Electrospun nanofibers provide a good platform to treat chronic wounds like diabetic foot ulcers

2021 ◽  
Author(s):  
Moataz Dowaidar
Keyword(s):  
Drug Delivery ◽  
Wound Healing ◽  
Diabetic Foot ◽  
Wound Closure ◽  
Chronic Wounds ◽  
Electrospun Nanofibers ◽  
Wound Management ◽  
Foot Ulcers ◽  
Diabetic Foot Ulcers

Chronic foot ulceration is one of the major comorbid challenges associated with the manifestation of Type-2 Diabetic Mellitus and is responsible for high mortality rates, requiring the development of a localized drug delivery system (DDS) that can deliver the drug payload while also facilitating wound closure. Although nanofibers may be produced in many ways, electrospinning is one of the most versatile methods. Nanofiber-based DDSs show a substantial influence on targeted drug delivery, faster wound healing, and chronic wound closure. Electrospun nanofibers have evolved over time from simple nanofibers to new generations of nanofibers such as blend, composite, core-shell electrospun, and hybrid nanofibers, each with unique physicochemical and mechanochemical properties, giving distinct advantages to the respective nanofibers for better diabetic wound management. Optimizing the parameters involved in the preparation of nanofibers, which can be classified as static, processing and environmental parameters, is critical for process reproducibility, ensuring the desired properties of nanofibers, maintaining uniformity and maximizing the performance of electrospinning. Electrospun nanofibers are a suitable platform for treating chronic wounds such as diabetic foot ulcers. However, clinically using nanofiber-based DDSs as a localized wound therapy platform requires comprehensive physicochemical and mechanochemical characterization, as well as rigorous in-vitro and in-vivo drug release and wound healing efficacy testing.

Sign in / Sign up

Export Citation Format

Share Document